CFLAR and breast carcinoma: In breast cancer stem cells, the silencing of cFLIP by siRNA or a chemical known as droxinostat [165], sensitised them to TRAIL-mediated effects, and the combination of both the cFLIP inhibition and the TRAIL induction resulted in a significant reduction in the tumour bulk, metastasis, and self-renewal of the breast CSCs.